Karim Fizazi

Karim Fizazi, MD, PhD is Head of the Department of Cancer Medicine at Institut Gustave Roussy in Villejuif, France, and Professor of Oncology at the University of Paris-Saclay, where he leads one of Europe's most prolific genitourinary oncology research programs. Prof. Fizazi is the principal investigator of the landmark LATITUDE trial (NEJM 2017), in which he designed and led the global phase III study that randomized 1,199 men with high-risk metastatic hormone-sensitive prostate cancer to abiraterone plus prednisone versus placebo added to ADT. LATITUDE demonstrated an OS HR of 0.62 (p<0.001) and was simultaneously published with STAMPEDE in the same NEJM issue, together establishing combination intensification as the new mHSPC standard of care worldwide. He also served as a key European investigator in the COU-AA-301 trial establishing abiraterone in post-docetaxel mCRPC, and led the CARD trial (NEJM 2019) demonstrating that cabazitaxel is superior to a second AR-targeted agent (enzalutamide or abiraterone) in mCRPC patients who have progressed after docetaxel and one prior AR-targeted therapy — a finding that transformed sequencing decisions in mCRPC. Prof. Fizazi has additionally made seminal contributions to understanding prostate cancer bone metastasis biology, characterizing the osteoblastic bone-forming lesion as distinct from other cancer bone metastases, and investigating the role of DKK1, endothelin axis, and RANKL in prostate cancer–bone interactions.